Osman Doğan

Osman Doğan

Auto-generated profile, based on publicly available information

Osman Doğan

Department of Bioengineering, Faculty of Life and Natural Science, Abdullah Gül University, Kayseri, Turkey https://ror.org/00zdyy359 https://www.isni.org/isni

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2022 in Beilstein Journal of Nanotechnology
Verified
Journal Article
Open access
PDF file
SUSedat Unal
Sedat Unal
ODOsman Doğan
Osman Doğan
YAYeşim Aktaş
Yeşim Aktaş
Intestinal cancers are the third most lethal cancers globally, beginning as polyps in the intestine and spreading with a severe metastatic tendency. Chemotherapeutic drugs used in the treatment of intestinal tumors are usually formulated for parenteral administration due to poor solubility and bioavailability problems. Pharmaceutically, clinical failure due to a drug’s wide biodistribution and non-selective toxicity is one of the major challenges of chemotherapy. In addition, parenteral drug administration in chronic diseases that require long-term drug use, such as intestinal tumors, is challenging in terms of patient compliance and poses a burden in terms of health economy. Especially in the field of chemotherapy research, oral chemotherapy is a subject that has been intensively researched in recent years, and developments in this field will provide serious breakthroughs both scientifically and socially. Development of orally applicable nanodrug formulations that can act against diseases seen in the distant region of the gastrointestinal tract (GIT), such as intestinal tumor, brings with it a series of difficulties depending on the drug and/or GIT physiology. The aim of this study is to develop an oral nanoparticle drug delivery system loaded with docetaxel (DCX) as an anticancer drug, using poly(lactic-co-glycolic acid) (PLGA) as nanoparticle material, and modified with chitosan (CS) to gain mucoadhesive properties. In this context, an innovative nanoparticle formulation that can protect orally administered DCX from GIT conditions and deliver the drug to the intestinal tumoral region by accumulating in mucus has been designed. For this purpose, DCX-PLGA nanoparticles (NPs) and CS/DCX-PLGA NPs were prepared, and their in vitro characteristics were elucidated. Nanoparticles around 250–300 nm were obtained. DCX-PLGA NPs had positive surface charge with CS coating. The formulations have the potential to deliver the encapsulated drug to the bowel according to the in vitro release studies in three different simulated GIT fluids for approximately 72 h. Mucin interaction and penetration into the artificial mucus layer were also investigated in detail, and the mucoadhesive and mucus-penetration characteristics of the formulations were examined. Furthermore, in vitro release kinetic studies of the NPs were elucidated. DCX-PLGA NPs were found to be compatible with the Weibull model, and CS/DCX-PLGA NPs were found to be compatible with the Peppas–Sahlin model. Within the scope of in vitro cytotoxicity studies, the drug-loaded NPs showed significantly higher cytotoxicity than a DCX solution on the HT-29 colon cell line, and CS/DCX-PLGA showed the highest cytotoxicity (p < 0.05). According to the permeability studies on the Caco-2 cell line, the CS/DCX-PLGA formulation increased permeability by 383% compared to free DCX (p < 0.05). In the light of all results, CS/DCX-PLGA NPs can offer a promising and innovative approach as an oral anticancer drug-loaded nanoformulation for intestinal tumors.

31 March 2021 in Ege Üniversitesi Ziraat Fakültesi Dergisi
Verified
Journal Article
Open access
PDF file
ODOsman Doğan
Osman Doğan
AAAysun Cebeci Aydin Aydin
Aysun Cebeci Aydin Aydin
Amaç: Bu çalışma ülkemizde geleneksel yöntemlerle üretilen gıda ürünlerinden laktik asit bakterilerinin izolasyonunu ve tanımlanmasını sağlamak amacıyla yapılmıştır.Materyal ve Yöntem: Çalışma kapsamında Van otlu peynir ve ekşi hamur örneği kullanılmıştır. Bu örnekler içerdikleri laktik asit bakterileri için çalışılmış ve tanımlanmaları için biyokimyasal ve PCR bazlı moleküler biyolojik tekniklere tabi tutulmuşlardır. Biyokimyasal testler kapsamında örnekler, Gram reaksiyonları, katalaz aktivitesi, gaz üretimi, 10oC ve 45oC'de, %6 ve %16 NaCl konsantrasyonda, pH 4.4 ve pH 9.6’da gelişim göstermeleri açısından incelenmiştir. Moleküler biyoloji deneyleri kapsamında ise tür ve suş düzeyinde tanımlama için PCR-RFLP, 16S rRNA gen dizileme ve RAPD-PCR teknikleri kullanılmıştır.Araştırma Bulguları: Bir dizi mikrobiyolojik deneylerin sonucunda 26 adet bakteri potansiyel laktik asit bakterisi olarak izole edilmiştir. Bunlardan 25 adedinin Lactobacillus, Pediococcus ve Enterococcus cinslerine ait olduğu tespit edilmiş ve tür ve suş düzeyinde tanımlanmaları sağlanmıştır. Kalan bir adet izolat ise Staphylococcus hominis olarak tanımlanmıştır.Sonuç: Çalışmamız sonucunda 25 adet laktik asit bakterisi gen dizileme ve RAPD-PCR teknikleri kullanılarak tür ve suş düzeyinde başarıyla tanımlanmıştır.

28 October 2021 in Turkish Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
SUSedat Unal
Sedat Unal
ODOsman Doğan
Osman Doğan
YAYeşim AKTAŞ
Yeşim AKTAŞ

21 August 2026 in Veterinarni Medicina
Verified
Journal Article
Open access
YGY Gunes
Y Gunes
YGY Gultekin
Y Gultekin
ODO Dogan
O Dogan
CACeren Anlas
Ceren Anlas
OUO Ustuner
O Ustuner
TBT Bakirel
T Bakirel